Literature DB >> 7898138

Neurologic manifestations of Churg-Strauss syndrome.

M Sehgal1, J W Swanson, R A DeRemee, T V Colby.   

Abstract

OBJECTIVE: To determine the frequency and the types of neurologic involvement in a series of patients with Churg-Strauss syndrome (CSS).
DESIGN: We reviewed the medical records of 47 consecutive patients with CSS who were examined at the Mayo Clinic between January 1974 and June 1992.
MATERIAL AND METHODS: The study patients were classified into two groups: (1) those with a histopathologically confirmed diagnosis of CSS who had evidence of either vasculitis or Churg-Strauss granuloma, the presence of asthma, and peripheral eosinophilia (more than 10% eosinophils) on at least one differential leukocyte count (N = 33) and (2) those with a clinical diagnosis of CSS who had evidence of vasculitis based on either multiple mononeuropathy or necrotizing cutaneous lesions, the presence of asthma, and peripheral eosinophilia (more than 10% eosinophils) on at least one differential leukocyte count (N = 14).
RESULTS: Of the 47 patients, 29 (62%) had neurologic involvement. Peripheral neuropathy was detected in 25 patients: 17 had multiple mononeuropathy, 7 had distal symmetric polyneuropathy, and 1 had an asymmetric polyneuropathy. Three patients had cerebral infarctions. Less commonly identified problems included radiculopathies, ischemic optic neuropathy, and bilateral trigeminal neuropathy. Asthma preceded the onset of neurologic involvement in all cases (mean duration, 6.7 years. Follow-up data, when available, showed that corticosteroid therapy usually yielded improvement or stabilization.
CONCLUSION: Neurologic involvement is common in CSS, usually manifesting as peripheral neuropathy. In this series of patients, asthma preceded the neurologic manifestations.

Entities:  

Mesh:

Year:  1995        PMID: 7898138     DOI: 10.4065/70.4.337

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  39 in total

1.  Coronary involvement in the Churg-Strauss syndrome.

Authors:  S Hellemans; J Dens; D Knockaert
Journal:  Heart       Date:  1997-06       Impact factor: 5.994

Review 2.  Immune mediated diseases and immune modulation in the neurocritical care unit.

Authors:  Gloria von Geldern; Thomas McPharlin; Kyra Becker
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

3.  Diagnosis and treatment of cerebral vasculitis.

Authors:  Peter Berlit
Journal:  Ther Adv Neurol Disord       Date:  2010-01       Impact factor: 6.570

4.  Subarachnoid haemorrhage as the first clinical manifestation of Churg-Strauss syndrome.

Authors:  Una-Marie Sheerin; Julio Barreto; Martin M Brown; Stefan Brew; Nicholas A Losseff
Journal:  J Neurol       Date:  2008-03-20       Impact factor: 4.849

5.  Churg-strauss syndrome with eosinophilic myocarditis: a clinical pathology conference held by the division of rheumatology at hospital for special surgery.

Authors:  Alana B Levine; George Kalliolias; Mark Heaney; Yoshimi Endo; Adam Gersten; Jonathan W Weinsaft; Robert F Spiera; Anne Bass; Doruk Erkan
Journal:  HSS J       Date:  2012-06-23

6.  Posterior reversible leukoencephalopathy syndrome as a presenting manifestation of p-ANCA-associated vasculitis.

Authors:  Upasana Vrijlal Patel; Nirajkumar Jagjivan Patel
Journal:  BMJ Case Rep       Date:  2014-05-22

7.  Non-atherosclerotic vascular disease in the young.

Authors:  Osvaldo Camilo; Larry B Goldstein
Journal:  J Thromb Thrombolysis       Date:  2005-10       Impact factor: 2.300

8.  Asthma, Foot Drop, and Palpable Purpura in a Young Woman.

Authors:  Gabriela Kuftinec; Maha Sami; Paul Aronowitz
Journal:  J Gen Intern Med       Date:  2017-06-15       Impact factor: 5.128

9.  Churg-strauss syndrome presented with hearing impairment and facial palsy.

Authors:  Jeong-Hyun Byun; Jong-Hoo Lee; In-Sung Choi
Journal:  Ann Rehabil Med       Date:  2014-12-24

10.  [A patient with Churg-Strauss syndrome presenting as Guillain-Barré syndrome].

Authors:  M Djukic; H Schmidt; C Mazurek; F König; S Schweyer; R Nau
Journal:  Nervenarzt       Date:  2008-04       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.